Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most
common enzymopathy in humans, is prevalent in tropical and subtropical areas where …

Safe treatment of Plasmodium vivax requires diagnosis of both the infection and status of
erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity because hypnozoitocidal …

Background Primaquine, the only available drug effective against Plasmodium falciparum
sexual stages, induces also a dose-dependent haemolysis, especially in glucose-6 …

Background Primaquine is essential for malaria control and elimination since it is the only
available drug preventing multiple clinical attacks by relapses of Plasmodium vivax. It is also …

Abstract Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is commonly seen in
malaria endemic areas as it is known to confer a selective advantage against malaria …

Introduction Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common
enzymopathy in the human population affecting an estimated 8% of the world population …

This user guide is designed to provide national malaria control programmes with general
information on glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with this …

Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency greatly hinders
Plasmodium vivax malaria radical cure and further elimination due to 8-aminoquinolines …

Background Glucose-6-phosphate dehydrogenase (G6PD) activity is dependent upon
G6PD genotype and age of the red blood cell (RBC) population, with younger RBCs having …

Abstract Objectives The World Health Organization recommends measurement of glucose-6-
phosphate dehydrogenase (G6PD) activity before initiation of 8-aminoquinoline therapy. A …